News & AnalysisRondo Therapeutics locks in $67m Series ARondo Therapeutics, a biopharmaceutical company, has raised $67 million in Series A funding.ByIris Dorbian2 March 2022•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs